e a plus sign (+) inside this box PTO/SB/08A (08-00)

Complete if Known

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

titute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/256,237 Filing Date February 24, 1999 First Named Inventor Heinrich HEIDTMANN et al. Group Art Unit 1642 M. Davis **Examiner Name**

(use as many sheets as necessary) Sheet of 1

Attorney Docket Number 38005-0087

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	g
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	0/2900
AD.	C01	DEBORAH DEFEO-JONES et al., "A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo", Nature Medicine, November 2000, pp. 1248-1252, Vol. 6, No. 11	
	C02	SAMUEL R. DENMEADE et al., "Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen", Cancer Research, June 15, 1998, pp. 2537-2540, Vol. 58	
	C03_	SAMUEL R. DENMEADE et al., "Specific and Efficient Peptide Substances for Assaying the Proteolytic Activity of Prostate-specific Antigen", Cancer Research, November 1, 1997, pp. 4924-4930, Vol. 57	
	C04	DENMEADE, SR et al., "Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer", Cancer J. Sci. Am, May 1998, 4 Supl. 1:S15-21	
	C05_	JUDAH FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease", Nature Medicine, 1995, pp. 27-31, Vol. 1, No. 1	
	C06	JUDAH FOLKMAN, "Clinical Applications of Research on Angiogenesis", The New England Journal of Medicine, December 28, 1995, PP. 1757-1763, Vol. 333, No. 26	
	A07_	JUDAH FOLKMAN et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia", Nature, May 4, 1989, pp. 58-61, Vol. 339	
	A08	BRUCE FURIE et al., "The Molecular Basis of Blood Coagulation", Cell, May 20, 1988, pp. 505-518, Vol. 53	
	A09	XIANMING HUANG et al., "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature", Science, January 24, 1997, pp. 547-550, Vol. 275	
	A10_	KHAN SR, et al., "In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts", Prostate, September 2000; 45(1):80-3	
	A11	JARI LEINONEN et al., "Complex Formation Between PSA Isoenzymes and Protease Inhibitors", The Journal of Urology, March 1996, pp. 1099-1103, Vol. 155	
	A12	HANS LILJA et al., "Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with α₁-Antichymotrypsin", Clin. Chem., 1991, pp. 1618-1625, Vol. 37, No. 9	
	A13_	LANCE ALLEN LIOTTA et al., "Quantitative Relationships of Intravascular Tumor Cells, Tumor Vessels, and Pulmonary Metastases following Tumor Implantation", Cancer Research, May 1974, pp. 997-1004, Vol. 34	·
4	A14	KENNETH W.K. WATT et al., "Human prostate-specific antigen: Structural and functional similarity with serine proteases", Proc. Natl. Acad. Sci. USA, May 1986, pp. 3166-3170, Vol. 83	

	Y			
Examiner Signature	M.T.	DAVIS	Date Considered	05/01/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

07/31/01

or 15 2012 Substitute of 15 2012 Substitute

AHallet # 27

Please type a plus sign (+) inside this box

Substitute for form 1449A/PTO

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, 16 persons are requised or respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known	
Application Number	09/256,237	
Filing Date	February 24, 1999	
First Named Inventor	Heinrich HEIDTMANN et al.	-
Group Art Unit	1642	5
Examiner Name	Minh Tam B. Davis	-
Attorney Docket Number	38005-0087	<u> </u>

				U.S. PATENT DOCUM	ENTS	
Examiner Initials *		U.S. P	atent Document	Name of Patentee or Applicant	Date of Publication of Cited	Pages, Columns, Lines, Where
	Cite No. ¹	Number Kind Code ² (if known)		of Cited Document	Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear
	-					
		 				
-						,
	<u> </u>	-				

1	···]	FOREIGN	PAT	CENT I	OCUMENTS			
	Examin er Initials*	Cite No. ¹	Office 3	eign Patent Docu Number ⁴	Kind Code ⁵ (if known)		Appli	of Patentee or cant of Cited ocument	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	${ m T_6}$
	Mi	C1	_	DE 197 01 141	Cl	4	1998	DE (traus	lated vers	in orchine tea	lon
		C2		WO 97/00949	Al	ij	1997	WO			
$\ $		C3	-	WO 96/06943	Al	3	1996	, wo			
/		C4	1	WO 97/00957	A1	1/	1997	wo			
	→	C5	_	. WO 96/12815	Al	5	1994	øWO			
1	\					ι					
							-				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

1 5 2002 3

Under the Paperwork Reduction Act of 1995 to persons are require to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449	A/PTO	TRADEMARK		Complete if Known	
INIEO		ON DIS	CLOSURE	Application Number	09/256,237	
				Filing Date	February 24, 1999	
SIAI	FMFN	IBYA	PPLICANT	First Named Inventor	Heinrich HEIDTMANN et al.	
				Group Art Unit	1642	7
	(use as man	y sheets as	necessary)	Examiner Name	M. Davis	
Sheet	2	of	2	Attorney Docket Number	38005-0087	<u> </u>

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2 -
Ms.	C6	NILSON BHK et al., "Targeting of retroviral vectors through protease-substrate interactions", <u>Gene Therapy</u> (1998) 3, pp. 280-286, Stockton Press, New York, NY, USA	
-			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.